Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:31:18.620Z.
Calculation as of: 2026-10-06T18:31:18.620Z.
Quote observation: 2026-10-06T18:28:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 36850a73a8dd64042e14cdb756c8aff586d88f9314e30134a37dd84cc424cdb4
PE RATIO
N/A
Market Cap
$3.64M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.60M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.96M
PE Ratio
N/A
TTM Avg
8.63
3Y Avg
8.63
5Y Avg
8.63
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | $3.71M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.71M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.64M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.56M | N/A | N/A | N/A | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.60M | N/A | N/A | N/A | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.96M | N/A | 8.63 | 8.63 | 8.63 |
| Nexalin Technology, Inc. (NXL)vs › | $3.55M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.02M | N/A | 1.58 | 1.58 | 1.58 |
| Moolec Science S.A. (MLEC)vs › | $3.46M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.27
Forward EPS (Est.)
$-18.02
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
